HC Wainwright Issues Pessimistic Estimate for COGT Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Investment analysts at HC Wainwright cut their Q3 2025 earnings per share estimates for Cogent Biosciences in a research note issued on Tuesday, July 8th. HC Wainwright analyst R. Burns now anticipates that the technology company will earn ($0.60) per share for the quarter, down from their previous estimate of ($0.59). HC Wainwright has a "Buy" rating and a $22.00 price target on the stock. The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Cogent Biosciences' Q4 2025 earnings at ($0.63) EPS, FY2025 earnings at ($2.33) EPS and FY2026 earnings at ($2.93) EPS.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The technology company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.04.

Several other brokerages have also commented on COGT. Needham & Company LLC restated a "hold" rating on shares of Cogent Biosciences in a research note on Tuesday, June 17th. Guggenheim reaffirmed a "buy" rating and issued a $17.00 target price on shares of Cogent Biosciences in a research report on Tuesday. Jefferies Financial Group upped their target price on Cogent Biosciences from $23.00 to $28.00 and gave the stock a "buy" rating in a research report on Monday. Leerink Partners upped their target price on Cogent Biosciences from $16.00 to $18.00 and gave the stock an "outperform" rating in a research report on Monday. Finally, Wedbush reaffirmed a "neutral" rating and issued a $10.00 target price on shares of Cogent Biosciences in a research report on Monday, June 30th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $17.60.

Cogent Biosciences Price Performance

Shares of NASDAQ:COGT opened at $10.40 on Thursday. The firm has a market capitalization of $1.18 billion, a PE ratio of -5.65 and a beta of 1.88. The business has a 50-day moving average of $6.33 and a two-hundred day moving average of $6.79. Cogent Biosciences has a 12 month low of $3.72 and a 12 month high of $12.61.

Institutional Trading of Cogent Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of COGT. Strs Ohio acquired a new stake in Cogent Biosciences during the first quarter valued at approximately $36,000. CWM LLC raised its stake in Cogent Biosciences by 11,869.9% during the first quarter. CWM LLC now owns 8,738 shares of the technology company's stock valued at $52,000 after buying an additional 8,665 shares in the last quarter. Schonfeld Strategic Advisors LLC acquired a new stake in Cogent Biosciences during the fourth quarter valued at approximately $78,000. Hsbc Holdings PLC acquired a new stake in Cogent Biosciences during the fourth quarter valued at approximately $81,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Cogent Biosciences during the fourth quarter valued at approximately $88,000.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.